A Large-Scale Acquisition Is Unlikely for Pfizer Until This Happens
Pharma titan Pfizer (NYSE: PFE) announced second-quarter earnings on Tuesday, but the drugmaker's performance was clearly a secondary issue for analysts and investors alike. Despite beating consensus on adjusted earnings per share and improving its full-year outlook for this same metric, for example, the drugmaker's shares still ended the day down 0.24%.
Pfizer's respectable Q2 earnings release was overshadowed by its glaring need to execute a large-scale acquisition, as well as management's unexpected pivot to in-line market opportunities as the company's main near-term growth driver.
Source: Fool.com